FDA's oncology adcomm to review PI3K inhibitors in blood cancers in April
An attractive cancer target is going to be in the hot seat at an FDA advisory committee on April 21.
The FDA’s oncologic drugs advisory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
